Amylyx Pharmaceuticals, Inc.

NASDAQ:AMLX

Biotechnology

Healthcare
$26.20 +0.93%

+$0.14 today

Market cap
$3.37B
Beta
-0.16
P/E (TTM)
-11.3
EPS (TTM)
-$1.36
52W Low $4.80High $18.61

Volume 1.76M

Average 1.21M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$123.34M

FY 2025 · Annual

Investing Cash Flow

$14.04M

FY 2025 · Annual

-81.4% YoY

Financing Cash Flow

$257.03M

FY 2025 · Annual

+73758.9% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(87.93M)(198.38M)49.27M(301.74M)(144.74M)
Depreciation & Amortization52K487K1.09M904K525K
Deferred Income Tax00000
Stock-Based Compensation3.14M21.71M37.16M33.04M27.65M
Change in Working Capital4.6M(1.64M)(65.66M)(45.83M)(1.08M)
Accounts Receivables(144K)(15.31M)(24.74M)39.6M383K
Inventory0(9.77M)(73.13M)(9.25M)0
Accounts Payables670K1.85M15.88M(19.1M)580K
Other Working Capital4.07M21.58M16.33M(57.08M)(2.05M)
Other Non-Cash Items5.35M(2.06M)(9.94M)145.99M(5.7M)
Operating Cash Flow(74.8M)(179.87M)11.92M(167.65M)(123.34M)
Capital Expenditures(353K)(2.53M)(1.24M)(157K)(138K)
Acquisitions (Net)0236.46M000
Purchases of Investments(49.05M)(415.87M)(300.83M)(231.99M)(231.82M)
Sales of Investments3M179.41M394.12M344M246M
Other Investing Activities0(236.46M)0(36.2M)0
Investing Cash Flow(46.41M)(238.99M)92.05M75.65M14.04M
Debt Repayment25.9M0000
Common Stock Issued0432.45M6.86M2.13M260.39M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(2.39M)(658K)(3.32M)(1.78M)(3.36M)
Financing Cash Flow158.51M431.79M3.54M348K257.03M
Effect of Forex Changes13K(65K)160K(438K)1.07M
Net Change in Cash37.31M12.87M107.68M(92.08M)148.8M
Free Cash Flow(75.15M)(182.4M)10.68M(167.8M)(123.48M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$144.7M
+ D&A$525.0K
+ Stock-Based Comp$27.6M
+ Deferred Tax$0
- Working Capital-$1.1M
- Other Non-Cash-$5.7M
= Operating Cash Flow-$123.3M
- Capex-$138.0K
= Free Cash Flow-$123.5M

Analysis

FY2025 free cash flow is -$123.5M. FCF conversion is 85.3% of net income. Operating cash flow was -$123.3M, with capex of -$138.0K. The largest bridge item is Stock-Based Comp at $27.6M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
4Statement of changes in beneficial ownershipNov 12, 2026
4Statement of changes in beneficial ownershipNov 12, 2026
4Statement of changes in beneficial ownershipNov 12, 2026
10-QQuarterly reportNov 5, 2026
8-KCurrent reportNov 5, 2026

Does AMLX generate free cash flow?

Amylyx Pharmaceuticals, Inc. (AMLX) generated -$123.48M of free cash flow in fiscal 2025.

How much operating cash flow does AMLX produce?

Operating cash flow was -$123.34M, before capital expenditures of $138,000.00.